Mon. 6 May 2024, 7:11am ET
Benzinga
Earnings, Earnings Beats, News
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.61) by 6.56 percent. The company reported quarterly sales of $4.216 million which beat the analyst consensus estimate of $3.214 million by 31.16 percent. This is a 23.51 percent decrease over sales of $5.512 million the same period last year.